The New HFA/ICOS Risk Assessment Tool to Identify Patients with Chronic Myeloid Leukaemia at High Risk of Cardiotoxicity
Open Access
- 31 March 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (3) , 1914-1919
Abstract
Aims: Tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulness of the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular risk in CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events (AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin. Methods and results: A retrospective single-centre observational study was carried out on 58 patients (32 men and 26 women; mean age ± SD: 59 ± 15 years) with CML treated with TKIs for a median period of 43 ± 31 months. Cardiological evaluation was performed and cardiovascular risk was estimated with SCORE risk charts and with the new risk assessment tool proposed by HFA/ICOS. AEs were recorded. According to SCORE charts and the new HFA/ICOS risk stratification tool, respectively, 46% (Group A1) and 60% (Group A2) of patients were at high–very high risk, and 54% (Group B1) and 40% (Group B2) at low–moderate risk. AEs were significantly more frequent in Group A1 than Group B1 (P value < 0.01) when considered overall; they were significantly more frequent in Group A2 than Group B2 either overall or considered individually. HFA/ICOS risk stratification tool was significantly more sensitive than SCORE (P < 0.01) in identifying patients at higher risk of cardiovascular toxicity. In addition, we did not find AEs in patients pretreated with aspirin. Conclusions: The new HFA/ICOS risk stratification model allows a more tailored cardiovascular risk stratification in patients with CML and it is more sensitive than SCORE charts.Keywords
This publication has 22 references indexed in Scilit:
- Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialBlood, 2018
- Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-upClinical Lymphoma Myeloma and Leukemia, 2017
- Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionAnnals of Hematology, 2016
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General PopulationJournal of Clinical Oncology, 2016
- Vascular Complications of Cancer ChemotherapyCanadian Journal of Cardiology, 2016
- 2016 European Guidelines on cardiovascular disease prevention in clinical practiceEuropean Heart Journal, 2016
- Vascular and Metabolic Implications of Novel Targeted Cancer TherapiesJACC, 2015
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingJournal of the American Society of Echocardiography, 2015
- Preclinical carotid atherosclerosis enhances the global cardiovascular risk and increases the rate of cerebro- and cardiovascular events in a five-year follow-upAtherosclerosis, 2010
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE projectEuropean Heart Journal, 2003